Akebia Launches Phase 2 Trial for Next-Gen Complement Inhibitor in Rare Kidney Diseases
AKBA sits 62% above its 52-week low of $0.823.
Summary
Akebia has initiated a Phase 2 basket trial for ebribafusp, a next-generation complement inhibitor, targeting three rare kidney diseases: IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The open-label study will enroll up to 30 patients, with primary safety endpoints and secondary efficacy measures including proteinuria and kidney function. This follows the June 2026 VOICE trial success for Vafseo, which demonstrated superior safety and was stopped early—reinforcing the company's momentum in kidney disease. Ebribafusp, acquired from Q32 Bio in late 2025, is designed to inhibit complement locally in tissues without systemic suppression, potentially offering a safer long-term option. Initial data is expected in 2027, making this a long-duration catalyst but a meaningful pipeline advancement for a $354M market cap company.
At the time of this announcement, AKBA was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $354.1M. The 52-week trading range was $0.82 to $3.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.